Carlsbad / San Antonio / St. Gallen / Honolulu / Barcelona / New York / Washington / DC / Rome / Los Angeles / Glasgow / /
Company
Novartis / PCCTC LLC / Genentech / Astellas Pharma / Prostate Cancer / Precision Biologics Inc. / Malecare / Prostate Cancer Clinical Trials Consortium LLC / Dana / Medivation / New England Journal / PCRP / Physicians’ Education Resource LLC / /
Country
Switzerland / Scotland / Italy / United States / Jamaica / Spain / /
Currency
USD / / /
Event
Business Partnership / FDA Phase / Funding / /
Facility
Annual PCF Scientific Retreat / Urology Research University of Kentucky College of Medicine / University of Washington / Memorial Sloan-Kettering Cancer Center / Cleveland Clinic / Beth Israel Deaconess Medical Center / Cedars-Sinai Medical Center / University of Wisconsin / University of Texas MD Anderson Cancer Center / New York University / Terminal Region DHT DBD AR Gene Rearrangement AR / Clark Atlanta University / Knight Cancer Institute / Johns Hopkins University / Terminal Region Target / /
IndustryTerm
cancer therapies / Cancer Therapeutics / treatment for prostate cancer / therapy for advanced prostate cancer / prostate cancer therapy / chemical castration / ideas and technologies / cancer treatment / cancer support / Prostate Cancer Treatment / /
MedicalCondition
Expert prostate cancer / metastatic prostate cancer / CRPC tumors / eventuCRPC tumors / castration-resistant prostate cancer / prostate cancer tumors / metastatic disease / prostate cancer / prostate cancer’s / tumor / prostate tumor / cancer / drugs targeting cancer / intratudrive prostate cancer / lethal metastatic cancer / AR variants prostate cancer / taught primary tumor / long-term chronic disease / advanced disease / both androgen-dependent and androgen-independent prostate cancer / resistant cancers / Fred Hutchinson Cancer Research cancer / future prostate cancer / patient’s disease / metastatic castration-resistant prostate cancer / castrationthe tumor / prostate resistant prostate cancer / cancers / advanced prostate cancer / lethal disease / disease / shock / Valuable new tate cancer / pain / human prostate cancer / prostate tumors / /
MedicalTreatment
endocrine therapy / surgery / immunotherapy / radiation / cancer therapy / cancer therapies / chemotherapy / hormonal therapy / /
Organization
University of Washington / New York University / the Johns Hopkins University / Cedars-Sinai Medical Center / DoD PCRP / American Association of Clinical Urologists / University of Kentucky College of Medicine and Markey Cancer Center Compelling / Department of Hematopathology / University of Texas / Department of Defense PCRP / Beth Israel Deaconess Medical Center / Johns Hopkins University / Knight Cancer Institute / Japanese Urological Association / Centers for Disease Control and Prevention / Clark Atlanta University / Congress / British Columbia Cancer Agency / Vivek Arora Center / U.S. Food and Drug Administration / Memorial Sloan-Kettering Cancer Center / Tulane / University of Florida / University of Wisconsin / /
Person
Steven Balk / Charles Sawyers / Marianne Sadar / Stephen Plymate / Mary Ellen / Michael / Nima Sharifi / Kyprianou / Jun Luo / Mary Ellen Taplin / Tomasz Beer / Vivek Arora / Scott / Charles Huggins / George Wilding / Tomasz M. Beer / Yan Dong / Philip Arlen / Shafiq Khan / Grant Writing / Timothy McDonnell / / /
Position
physician / General / Professor / critical driver / principal driver / investigator / President / Chief Medical Officer / and Chief Executive Officer / leading investigator in prostate cancer research / editor / principal investigator / Professor and Deputy Chair / member / /
Product
bicalutamide / testosterone / ketoconazole / EPI-001 / Name Drug / APC-100 / CYP17A1 / /
ProvinceOrState
Minnesota / New York / California / Texas / Wisconsin / Florida / Arkansas / /
PublishedMedium
the Uninoteworthy advances / the New England Journal of Medicine / /
Technology
radiation / high-throughput screening / chemotherapy / treating cancer / cloning / DNA binding / drug development / /
Prostate Cancer Research Program (PCRP) PCRPerspectives Volume 4, Number 2 – October[removed]In This Issue